Recent Press Releases

Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US

With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a...

Pfizer Commits to Further Reduce Price for Prevenar 13 in the World's Poorest Countries Through 2025

Pfizer Announces New Commitments During Gavi's Pledging Conference Monday, January 26, 2015 - 4:12pm EST Pfizer Inc. (NYSE:PFE) today announced new commitments aimed at ensuring the...

MSF responds to Pfizer announcement of pneumococcal vaccine price reduction

Ahead of tomorrow's donor replenishment conference for Gavi, The Vaccine Alliance, taking place in Berlin, pharmaceutical company Pfizer has announced it is cutting the price on its pneumococcal...

Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines

Proprietary DepoVax(TM) Technology Works with Multiple rPA Antigens HALIFAX, NOVA SCOTIA, Jan 28, 2015 (Marketwired via COMTEX) -- Immunovaccine Inc. ("Immunovaccine") (IMV), a...

Tau-based Vaccines Could Transform Early Alzheimer's Disease Treatment, says GlobalData Analyst

LONDON, UK (GlobalData), 27 January 2015 - While current treatments for Alzheimer's Disease (AD) are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective...

Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70

THOUSAND OAKS, Calif., Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2014. Key results include: For the fourth quarter,...

Vaccinogen Completes Initial Closing of an $80 Million Financing

FREDERICK, Md., Aug. 25, 2014 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced today that it completed the initial closing of a private placement...

Regulatory update on three-part transaction with Novartis

GlaxoSmithKline plc (LSE/NYSE: GSK) has today received clearance from the European Commission of its proposed three-part transaction with Novartis which includes the acquisition of Novartis's...

Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial

23 January 2015 Issued: London, UK Healthcare workers among those to be vaccinated in large-scale trial involving up to 30,000 people due to start in the coming weeks GSK has announced that the first...

Prevenar 13®* Receives CHMP Positive Opinion For Prevention Of Vaccine-Type Pneumococcal Pneumonia in Adults

January 22, 2015 11:21 AM Eastern Standard Time NEW YORK--()--Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency's Committee for Medicinal Products for...

Specialty Vaccine Company PaxVax Appoints Nima Farzan as President

REDWOOD CITY, Calif. – January 21, 2015 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Nima Farzan as President and...

Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine

First Clinical Study in Infectious Disease Indication with a DepoVax(TM)-Based Vaccine HALIFAX, NOVA SCOTIA, Jan 20, 2015 (Marketwired via COMTEX) -- Immunovaccine Inc....

Aduro Biotech Reports Long-term Survival and Immune Biomarker Data From Phase 2 Clinical Trial of Its Immuno-oncology Regimen in Patients With Pancreatic Cancer

BERKELEY, Calif.--(Business Wire)--Aduro Biotech, Inc. today announced that seven pancreatic cancer patients treated with its combination immuno-oncology regimen in a 93-patient Phase 2a clinical...

Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative

NEW BRUNSWICK, N.J., Jan. 16, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government...

GSK GLOBAL VACCINES CHAIRMAN MONCEF SLAOUI JOINS IAVI BOARD OF DIRECTORS

The International AIDS Vaccine Initiative (IAVI) is pleased to announce that Dr. Moncef Slaoui, Chairman, Global Vaccines, GlaxoSmithKline (GSK), has joined its Board of Directors. "Moncef...

Aduro Biotech Announces Phase 2 Clinical Trial Results for Pancreatic Cancer Combination Immunotherapy Published in Journal of Clinical Oncology

Aduro Biotech Announces Phase 2 Clinical Trial Results for Pancreatic Cancer Combination Immunotherapy Published in Journal of Clinical Oncology - Statistically Significant Survival Benefit...

WHO grants approval for safe, effective meningitis A vaccine for infants

New technology already has achieved dramatic drop in major cause of deadly epidemics in sub-Saharan Africa GENEVA - 9 JANUARY 2015 - The World Health Organization (WHO) has opened the door to routine...

Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen

NEW BRUNSWICK, N.J., Jan. 6, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development...

Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN® Filo and Janssen's AdVac® technology

First human trial of the MVA-BN® Filo/AdVac® preventative Ebola vaccine regimen initiated in the UK Additional trials soon to be initiated in United States and Africa Company now expects...

NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award

NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award AMES, Iowa and KENILWORTH, N.J., Dec. 22, 2014 (GLOBE NEWSWIRE) -- NewLink...